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Summary.-The levels of polyamines (putrescine, spermidine and spermine) in
erythrocytes and plasma were studied using Cloudman S-91 melanoma grown in the
lungs of DBA/2 mice. Polyamine levels and the numbers of tumour-cell colonies in
the lungs were determined at weekly intervals. Putrescine levels in both erythrocytes
and plasma significantly increased 1 week after tumour inoculation. Three weeks
after inoculation, however, putrescine levels in the erythrocytes showed a greater
increase than those in plasma. Spermidine and spermine levels were initially high at
2 weeks in plasma and at4 weeks in erythrocytes. However, by6 weeks the spermidine
levels showed a greater increase in erythrocytes than in plasma. These data suggest
that erythrocytes may absorb and store polyamines released into the circulation.
This finding was subsequently applied to human studies. Fifty-two untreated
patients with solid tumours were examined in the preoperative period. All erythro-
cyte polyamine levels from patients were significantly higher than those from control
subjects. Plasma spermidine levels in patients were significantly higher than those in
controls, whereas plasma putrescine and spermine levels showed no significant
increase. The frequency of raised levels of putrescine, spermidine and spermine in
erythrocytes was significantly greater than in plasma. These results suggest that
polyamine levels in erythrocytes may provide useful information for the detection of
cancer.
THE NATURALLY occurring polyamines
are known to have important regulatory
functions in growth and proliferation of
cells (Cohen, 1971; Bachrach, 1973).
Since Russell (1971) first reported that
cancer patients excreted an increased
amount of polyamines in their urine, a
number of papers have been published on
raised polyamine levels in urine (Dreyfuss
et al., 1975; Lipton et al., 1975; Waalkes
et al., 1975) and plasma or serum (Nishioka
& Romsdahl, 1974; Russell & Russell,
1975; Nishioka & Romsdahl, 1977;
Nishioka et al., 1977; Chaisiri et al., 1979)
of cancer patients. At present, however,
the clinical application of polyamine
determinations as a diagnostic tool for
cancer detection has been limited by the
low sensitivity and lack of specificity of
polyamine detection in urine or plasma.
Recently, high polyamine levels have
been found in erythrocytes from patients
with cancer (Saeki et al., 1978; Cooper et
al., 1978). These reports dealt with a
limited number of patients. At this time,
very little information is available on the
level ofpolyamines in erythrocytes during
the cancer state in humans. Although
some reports also indicated high levels of
polyamines in tumour tissues or urine of
tumour-transplanted animals (Neish &
Key, 1967; Russell & Levy, 1971; Ander-
sson & Heby, 1972) and during carcino-
genesis (Fujita et al., 1976, 1978; Perin &
Sessa, 1978; Scalabrino et al., 1978), no
values have been reported for polyamines
in whole blood oftumour-bearing animals.
Therefore, using an animal model system,
we investigated the fluctuation of poly-
amine levels in erythrocytes and plasmaH. TAKAMI AND K. NISHIOKA
at various times after inoculation of
melanoma cells. Based on these results, an
attempt was made to study erythrocyte
polyamine levels relative to plasma poly-
amine levels in cancer patients, and to
examine the potential usefulness of
erythrocyte polyamines as biological mar-
kers for cancer.
MATERIALS AND METHODS
Experimental mouse melanoma.-Male in-
bred DBA/2 mice, aged 5 weeks (18-21 g) were
purchased from Timco Breeding Laboratories
(Houston, Texas, U.S.A.), and fed a standard
laboratory diet ad libitum.
The melanoma cells used were maintained
in tissue culture in Eagle's minimum essential
medium (MEM) supplemented with 10%
foetal calf serum (Gibco, Grand Island, N.Y.,
U.S.A.). One-tenth ml of the cultured cells
(106 cells/ml) suspended in MEM was injected
into the tail vein. Each week thereafter at
least 6 mice were sacrificed to collect blood.
The lungs were examined macroscopically for
pigmented melanoma colonies, which were
then counted. Control mice were injected
with 0-1 ml of MEM and sacrificed in groups
of4 (minimum). Blood was drawn from retro-
orbital plexus under ether anaesthesia and
placed in heparinized tubes. All blood was
collected between 10.00 and 11.00 to avoid
difference due to circadian rhythm (Halberg
et al., 1976).
Patients with solid tumours.-The 52 (18 M;
34 F) preoperative patients examined (mean
age, 59) with solid tumours (breast, 16;
colorectum, 14; lung, 8; melanoma, 7; mis-
cellaneous, 7) had no previous treatments,
blood transfusions or other diseases. The
control subjects were 11 (5 M; 6 F) healthy
closely age-matched individuals (mean age,
55). Premenopausal females were excluded
from this study due to known fluctuation in
polyamine levels during the menstrual cycle
(Lundgren et al., 1976). Heparinized blood
was collected during the fasting state in the
morning.
Preparation ofsamples and determination of
polyamines-.Whole blood was immediately
centrifuged at 500 g for 20 min after collec-
tion. The plasma was then removed for poly-
amine assay, and the buffy coat leucocytes
were carefully aspirated from the erythro-
cytes (Cooper, et al., 1978; Saeki, et al., 1978).
Aliquots of plasmna (0-3-0-35 ml from the
mouse and 5 0 ml from the human) were used
for polyamine analysis. The erythrocytes were
subsequently washed with 3 volumes of cold
physiological saline, centrifuged, and the
buffy coat leucocytes aspirated as above. This
procedure was repeated twice more. After
thoroughly mixing the packed erythrocytes,
aliquots of the erythrocyte fraction (0-2 ml
from mouse sample and 1I0 ml from human
sample) were used for preparation of poly-
amine samples.
Plasma and erythrocytes thus obtained
were treated with trichloroacetic acid (TCA)
as follows, according to the procedures of
Durie et al. (1977) with some modifications.
Plasma was mixed with 100% TCA to a final
concentration of 500 TCA. An additional
volume of50o TCA (1-0 ml for mouse sample,
3 0 ml for human sample) was then added to
the plasma. In the erythrocyte samples, 5%
TCA solution was added to the erythrocytes
first, followed by the 100% TCA, to avoid
insufficient mixing which occurs if 100% TCA
is added directly to erythrocytes. The samples
were then mixed thoroughly for a minimum
of 3 min and left standing at 4°C for 30 min.
After centrifugation at 5,000 g for 20 min, the
supernatants were collected and pellets re-
extracted twice with 500 TCA as above. The
supernatants were combined and lyophilized.
These samples were hydrolysed in 6N HCI
for 16 h at 104°C, extracted twice with ether,
and again lyophilized. The residues were dis-
solved in 0 5 N HCI and analysed for poly-
amines, using a Durrum D-500 high-pressure
amino acid analyser (Russell & Russell, 1975;
Cooper et al., 1976). The recoveries of putres-
cine, spermidine and spermine wiere 88.2%,
77-70o and 84-10o, respectively, in mice,
whilst in humans recoveries were 85.0%,
78.4% and 86 4%, respectively.
RESULTS
Erythrocyte and plasma polyantine levels in
melanoma-bearing and normal mice
In melanoma-bearing mice, no tumour
colonies in the lungs were seen in the first
3 weeks after inoculation (Table I). Lung
colonies appeared at 4 weeks, becoming
confluent at 7 weeks. Metastases were not
found, macroscopically or microscopically,
in any other organs. All mice survived for
at least 7 weeks after inoculation.
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TABLE I.-Distribution of tumour colonies
in lungs of mice after i.v. injection of
Cloudman S91 melanoma cells
Number of tumour
colonies per mouse*
0,0,0,0,0,0
8,25,18,9,6,11,30
89, 101, 132, 163, 90, 123
200-400
confluent
No.
mice
6
7
6
7
6
* Macroscopically visible tumour nodules.
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FIG. 2.-Changes of levels of spermidine in
erythrocytes and plasma after inoculation
of melanoma cells into mice. See legend to
Fig. 1. for explanation of symbols.
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FIG. 1.-Changes of levels of putrescine in
erythrocytes and plasma after inoculation
of melanoma cells into mice. 0: erythro-
cytes from melanoma-bearing mice; 0:
erythrocytes from control mice; A: plasma
from melanoma-bearing mice; A: plasma
from control mice. Levels are expressed as
nmol/ml packed erythrocytes and nmol/ml
plasma.
As shown in Fig. 1, putrescine levels in
both erythrocytes andplasma significantly
increased as early as 1 week after inocula-
tion, reaching the maximum level at 4
weeks. However, after 3 weeks putrescine
levels in erythrocytes showed a much
greater increase than those in plasma.
Putrescine levels in erythrocytes were 2-4-
3-5 x those of controls during the 3rd to
7th week after inoculation, whereas in
plasma they were 1-6-2*3 x those of con-
trols at corresponding weeks. Figs 2 and 3
show that both spermidine and spermine
levels in plasma significantly increased
2 weeks after inoculation, and remained
at this level until 5 weeks. Subsequently,
mild decreases ofspermidine and spermine
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FIG. 3.-Changes of levels of spermine in
erythrocytes and plasma after inoculation
of melanoma cells into mice. See legend to
Fig. 1 for explanation of symbols.
levels were seen. On the other hand,
spermidine and spermine levels in erythro-
cytes significantly increased at 4 weeks,
continuing markedly to increase during
the observation. Beyond 6 weeks the
spermidine and spermine levels in erythro-
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TABLE II. Erythrocytes and plasma polyamine levels of control su;bjects and patients wvith
solid turmours
Contirol stubjects
n = 11
Patients with
solicl turnours
n=52
% ofpatients with
withl highi levels*
P§
Erytlhi ocytes I'lasma
Puttrescirle Spermidinie Spermine lutrescine Spermidine Sperminie
0 166+0050 11-76+2 74 721 + 2-29 0 108+00027 0 129+0-042 0038+0017
0395+0 267 22-76+9-97 14-96 + 662 0 142+00085 0-176+0±083 0045 ++0025
62 5
< 0*001
64 8
< 0*001
64-7
< 0 00 1
21*6
NS
294-
<0*05
1909
NS
Eiytlrocyte levels are exprossed1 as inmol/ml packed erytluocytes; andl plasma levels as iimol/ml. Mlean
+s.cl.
* More than mean + 2 s.d. of conitrol.
§ Student's t test between control subjects andl pativntts.
cytes increased much more than in plasma.
For example, spermidine levels in erythro-
cytes were 4-6 and 5-2 times the controls
at 6 and 7 weeks after inoculation,
respectively, whereas in plasma they were
2*6 and 2 2 times the controls at the
corresponding weeks. Similarly, spermine
levels in erythrocytes were 2-0 and 3 0
times those of the controls at 6 and 7
weeks, respectively, while levels in plasma
were 1P7 and 2-2 times those ofthe controls
at the corresponding weeks.
Erythrocyte and plasma polyamine levels in
patients with solid tumours and in control
subjects
As presented in Table II, the levels of
putrescine, spermidine and spermine were
raised in erythrocytes of more than 60%
of the patients with cancer, and signifi-
cantly higher than those in control sub-
jects. On the other hand, less than 30% of
the cancer patients had raised levels of
putrescine, spermidine, and spermine in
their plasma. While spermidine levels of
plasma from cancer patients were found
to be significantly higher than those of
control subjects, putrescine and spermine
levels from cancerpatients were not signifi-
cantly higher than controls. In comparing
frequencies of high polyamine levels be-
tween erythrocytes and plasma, there
were significantly more high levels of
putrescine, spermidine and spermine in
erythrocytes than in plasma (X2 analysis:
putrescine and spermine, P < 0-0005;
spermidine, P < 0 00025).
DISCUSSION
It was recently demonstrated (Cohen
et al., 1976; Cooper et al., 1976; Saeki et al.,
1978) that erythrocytes contain more than
80% ofthe spermidine and more than 7000
of the spermine in whole blood. Based on
these findings, preliminary studies (Cooper
et al., 1978; Saeki et al., 1978) have demon-
strated that erythrocyte polyamine levels
from patients with solid tumours were
raised. These preliminary human studies
seemed to warrant an investigation of the
behaviour of erythrocyte polyamines in
an animal tumour model.
In our animal model, putrescine was
simultaneously high in both plasma and
erythrocytes during the early phases of
melanoma growth, whereas significant
increases in spermidine and spermine
levels in plasma were detected earlier Ilhan
in erythrocytes. However, the increased
levels of putrescine, spermidine and sper-
mine in erythrocytes were much greater
than in plasma in the latter phases of
tumour growth. This observation indicates
that erythrocytes from patients with solid
tumours may absorb and store the poly-
amines released from growing tumours into
circulating blood. Cooper et al. (1978) have
suggested that the polyamines produced
by tumours were absorbed into erythro-
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cytes to maintain equilibration of poly-
amines among tumours, plasma, erythro-
cytes and leucocytes. Saeki et al. (1978)
also pointed out that erythrocytes may
work as polyamine carriers in the systemic
circulation.
The results from our animal studies
were used to design our investigation of
polyamine levels in cancer patients.
Erythrocyte polyamine levels in patients
with solid tumours were significantly
higher than in control subjects. We also
found that the frequency of high poly-
amine levels in erythrocytes was signifi-
cantly greater than in plasma. Measuring
the polyamine levels in erythrocytes seems
to be much more sensitive for the detection
of cancer than measuring the levels in
plasma. Although Cooper et al. (1978)
separated whole blood into the fractions
of erythrocytes, mononuclear leucocytes,
polymorphonuclear leucocytes, platelets
and plasma for polyamine analysis, only
one patient with lung cancer was ex-
amined. Saeki et al. (1978) reported raised
polyamine levels in erythrocytes from 10
patients with solid tumours, although
erythrocyte polyamine levels were not
compared with plasma levels.
The question raised by these results is
wherethe circulatingpolyamines inplasma
are bound and localized. In examining
polyamine levels in erythrocytes age-
separated by density, Cooper et al. (1976)
found that polyamine levels in old erythro-
cytes were significantly less than in young
erythrocytes. Consequently, since most of
erythrocyte components lost during aging
are membrane associated, polyamines may
be associated mostly with the cell mem-
brane. However, the polyamine levels in
whole white ghost erythrocyte membranes
from control subjects were only 1.5% to
2.0% of those in the soluble fraction, and
showed no significant difference from those
from cancer patients who had raised levels
of polyamines (Takami & Nishioka, un-
published). Further studies are in progress
to determine the binding site of tumour-
released polyamines on to the erythro-
cytes.
Although polyamine levels are also high
in patients with diseases other than cancer
(Dreyfuss et al., 1975; Waalkes et al., 1975)
the possible clinical application of poly-
amines as a useful biological marker of
cancer make such a study a promising
venture.
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